| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Mounjaro | $3.09B | $3.11B | $3.53B | $3.84B | $5.20B | $6.52B | $7.41B | $8.66B |
| Zepbound | $1.24B | $1.26B | $1.91B | $2.31B | $3.38B | $3.59B | $4.26B | $4.16B |
| Verzenio | $1.33B | $1.37B | $1.56B | $1.16B | $1.49B | $1.47B | $1.60B | $1.30B |
| Jardiance | $769.60M | $686.40M | $1.20B | $1.01B | $690.00M | $959.00M | $768.60M | $1.11B |
| Other oncology | $826.80M | $862.50M | $997.00M | $789.00M | $924.30M | $937.40M | $1.00B | $966.00M |
| Trulicity | $1.25B | $1.30B | $1.25B | $1.10B | $1.09B | $1.05B | $1.04B | $919.00M |
| Other cardiometabolic health | $1.17B | $1.05B | $1.22B | $945.00M | $980.40M | $1.06B | $1.02B | $905.00M |
| Taltz | $824.70M | $879.60M | $951.60M | $762.00M | $847.60M | $901.50M | $1.05B | $733.00M |
| Other immunology | $257.70M | $306.10M | $339.40M | $326.00M | $408.00M | $460.90M | $489.00M | $470.00M |
| Neuroscience | $339.50M | $351.80M | $393.60M | $272.00M | $344.00M | $315.70M | $459.20M | $382.00M |
| Total | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |